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Summary: This paper deals with the study of CEA levels in urine from healthy control subjects, of patients with
bladder carcinoma or previous bladder carcinoma, and other groups of patients. In 53% of the patients with bladder
carcinoma and without urinary infection, urinary CEA was increased. There were no false positive results. It is con-
cluded that urinary CEA is a valuable aid in the detection of malignant tumour growth in the bladder. The results
are compared with several tumour parameters, e.g. tumour size, stage of disease and histological parameters.
Evidence is presented that CEA in infected urine is not produced by bacteria and that, like soluble vaginal excretory
products, this substance has antigenic groupings in common with CEA from bladder tumours.
Carcino-embryonales Antigen im Urin von Patienten mit Blasenkrebs
Klinische Bedeutung des carcino-embryonalen Antigens, 2 Mitteilung
Zusammenfassung: Die Konzentration des carcino-embryonalen Antigens (CEA) im Urin von Gesunden, von Patienten
mit Blasenkrebs oder von Patienten, welche vorher Blasenkrebs hatten und von anderen Gruppen von Patienten wurde
bestimmt. In 53% der Fälle von Patienten mit Bläsenkrebs, aber ohne Harnwegsinfektion, waren die CEA-Werte
erhöht. Bei Patienten, die mit Erfolg behandelt wurden, gab es keine erhöhten CEA-Werte. Daraus läßt sich schließen,
daß die CEA-Bestimmung im Urin eine wertvolle Hilfe bei der Diagnostik von malignen Prozessen in der Blase dar-
stellen kann. Die Ergebnisse wurden mit verschiedenen Parametern verglichen, z. B. Tuinorgröße, Krankheitsstadium
und histologischem Befund. CEA, welches in infiziertem Urin gemessen wird, wird nicht von Bakterien produziert,
hat aber antigene Gruppen mit dem CEA aus Blasentumoren gemein.
Introduction 30 male patients. In a recent report (5) the same group
extended their original work. The latter report indicated
Carcino-embryonic antigen (CEA) was first described by
 yaluos < 35 ^  as normal fange for femaleS) which
Gold&Freedman (1). Studies on urinary carcino-
 is quite diffefent from ^  range (< no ^ /]} used in
embryonic antigen levels were not undertaken until 1972.
 a previous study Guimn et d (6) reported that the
In two interesting reports, Hall et al. (2, 3) presented
 mean C£A ]evd in urines of 24 patients with
data indicating a possible correlation between increased
 bladder carcinoma was significantly higher than that
amounts of urinary CEA and bladder carcinoma.
 Qf nonnai subjects.
CEA1) levels in urine from healthy female subjects,
however, showed widely varying and sometimes very The above mentioned authors remarked that more data
high levels. The same group extended their studies of are needed before the clinical value of CEA assays in
male patients and reported elevated values (> 35 /*g/l) in urine can be definitely established. This study was
52 per cent of 45 patients (4). This was a lower inci- «Jarted in °rder *° extend available information on the
dence than that in their original study (2), covering clinical ^  ^  CEA measurements m the urine of5 J
 ^ patients with bladder carcinoma. An attempt was
. made to correlate several parameters of the tumour
*) Abbreviation: CEA = carcino-embryonic antigen. with urinary CEA levels. In addition, some experiments
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were performed to gain more insight into the origin
of the substance which is measured in the radio-
immuno-assay for CEA in the urine of patients with
bladder carcinoma.
Materials and Methods
Unless stated otherwise, urines were collected during cystocopy.
Part of the samples of each urine was used to make cultures.
The other pait of the samples was then dialysed for four hours
against phosphate buffered saline (50 mmol/1 phosphate,
0.1 mmol/1 K2EDTA; pH 7.4), using cellulose acetate tubing.
The dialysed portions were stored frozen until assay of CEA.
Urinary cultures were grown on gel plates within a few hours
of collection. In a number of cases the organisms were identi-
fied. Urinary infection was considered to be present if more
than 108 colonies /I were found. CEA was measured in duplicate
by the procedure described in a previous paper. Assays were
performed in dialysed urines, undiluted and after dilution 1:2
with phosphate buffered saline (7). Extracts were made of
bacterial cultures of urine samples. Bacterial colonies were
removed from the plates and powdered in a "microdismembra-
tor" (Braun, Melsungen, Germany) at low temperature (cooling
'in liquid nitrogen). The complete procedure has been described
elsewhere (8). The powder was dissolved in the urine of healthy
control subjects, containing less than "20 Mg/1 CEA. In the
solution, thus prepared, CEA was measured. Vaginal and
cervical discharges from women who were clinically free of
carcinoma, were mixed with the urine of control subjects
« 20 Mg/1 CEA) for two hours at room temperature. The
mixture was centrifuged for 10 minutes at 3.000 r.p.m.
Control subjects
In order to establish normal CEA values, CEA was estimated
in the urines of 78 healthy subjects, 41 male and 37 female. In
these cases midstream instead of catheter urine was taken. The
ages varied between 20 and 61 years (male) and between 18 and
59 years (female). Three of the male subjects used medication.
Thirteen of the female subjects used oral contraceptives and
three used other medication.
Patients
The patients could be divided in 4 groups:
1. 78 patients, 60 male and 18 female, suffering from bladder
carcinoma. Their ages varied between 42 and 93 years. The
classification of their disease was established according to
criteria of the Union Internationale contre le Cancer (9).
2. 134 patients, 110 male and 24 female, who had previously
suffered from bladder carcinoma and showed no clinical
evidence of the disease after treatment. The ages varied from
28 to 93 years.
3. 4 female patients with carcinomas of organs other than the
bladder, i.e. 3 with cervical carcinoma and one with pyelum
carcinoma. They had invasive tumour growth into the
bladder as confirmed by cystoscopy but no infection of the
urinary tract.
4. 19 patients who had an infection of the urinary tract but
were not suffering from carcinoma, either at the time of
urine collection or previously.
In all cases urinary CEA was estimated without knowledge
of the clinical status of the subjects involved. Diagnosis was
assessed and treatment given without reference to the CEA
values. Therapeutic results were assessed and recorded independ-
ently of the results of the CEA assays.
Results
CEA levels in urine
Healthy controls
The results of CEA estimates in the urines of 41 males
and 37 females are shown in figure 1, column I and II.
Age, use of medication, length of menstrual cycle or
time of urine collection in relation to the menstrual
cycle had no demonstrable influence on the data. None
of the subjects had a urinary infection. One woman,
whose CEA level in midstream urine was 87 μg/l,
allowed us to collect urine again, but with a catheter.
Contrary to the midstream urine, the catheter urine
contained less than 30 μ%1\ CEA.
Patients with bladder carcinoma
Figure 1 (column IV and V) shows the results of
urinary CEA measurements in 53 patients without and
25 patients with urinary infection. Patients of both
groups had evidence of bladder carcinoma. Of the 53
patients without urinary infection, 22 out of 41 men
and 6 out of 12 women showed a urinary CEA excretion
higher than 30 μg/l. There was no indication that para-
meters such as age», sex, time of diagnosis and previous
treatment influenced the results.
Patients with previous bladder carcinoma
Urinary CEA was measured in 113 patients without
urinary infection and 21 patients with urinary infection.
None of these patients showed evidence of bladder car-
cinoma at the time of the investigation. The data are
presented in figure 1 (column VI). Of these subjects,
92 had a normal bladder wall at the time of the urine
collection; 18 showed a bladder with one or more
papillomes, i. e. non-invasive bladder carcinoma and
3 appeared to have a radiation ulcus. Figure 1 (column
Ml) gives the results in 21 cases with a urinary infection.
Patients with primary carcinoma of other organs
Three patients (with cervical carcinoma) had CEA levels
above 30 μg/l3 the patient with pyelum carcinoma had a
CEA level below 30 //g/l.
Patients with urinary infection only
Figure 1 (column III) shows the CEA levels in the urines
of 19 patients with urinary infection. These patients
never had evidence of any carcinoma.
Relatip.il of urinary CEA to several parameters
Size of the tumour
In 45 patients with bladder carcinoma but without
urinary infection the results of CEA estimation in urine
were considered in relation, to the diameter of the
tumour, which was roughly measured at cystocopy.
The diameter is supposed to be representative of the
part of the tumour which is in contact with the bladder
lumen, The data are listed in table 1.
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Fig. 1. Urinary CEA levels in patients and normal subjects.
Tab. 1. Relation of urinary CEA to tumour diameter. Tab. 2. Relation of urinary CEA to stage of disease.
Diameter
of the
tumour
>5 cm
3-5 cm
<3cn
CEA (Mg/l)
> 100 30-100
7 12
3
3
<30
10
5
5
Stage
of the
disease
T4
T3
TI
>100
3
3
1
CEA (Mg/1)
30-100
11
5
3
2
<30
10
5
7
2
Stage of disease
Table 2 lists several ranges of CEA levels according to
the clinical stage (9) of disease in 52 patients.
Histology
In 34 patients, with bladder carcinoma but without
urinary infection, histological findings were-compared
with the result bf the nearest CEA estimation. The
results are shown in table 3.
Additional experiments
We considered the possibility that elevated CEA levels
in infected urine and in urine of female controls might
be caused by interference in the CEA assay of excreted
bacterial products and contamination of urine by
vaginal or cervical secretion, respectively. Urinary
extracts of homogenized bacteria, prepared as described
under "Materials and Methods", were assayed for CEA.
The bacteria studied were E. coli, Enterococcus and
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Tab. 3. Histological parameters of bladder carcinoma in relation
to urinary CEA.
CEA (Mg/1)
Histology
>100 30-100 <30
Type
Papillary
Differentiation
Polymorphism
Depth of
invasion
Inflammatory
infiltrate
transitional cell
carcinoma
squamous cell
carcinoma
undifferentiated
carcinoma
-
none
poor
moderate
well
slight
moderate
severe
none
lamina propria
muscuiaris
non-classifiable
none
slight
moderate
severe
4
-
1
0J
2
1
1
2
1
_
2
3
3
2
-
_
3
1
1
7
-
3
7j
7
3
6
' 1
2
4
4
_
4
5*)
1
2
2
2
4
14
1
4
8ο
11
4
3
7
5
3
5
11
1
9
7
1
1
4
8
6
*) One of these patients had a tumour, growing outside through
the bladder wall.
Proteus. All extracts showed CEA levels below 30 /ig/1.
Non-infected urines with CEA levels below and above
30 Mg/1 were left standing covered at room temperature
for one day. The samples were then tested for CEA and
bacterial content. In some cases cultures were positive.
No changes in CEA levels were observed. Extracts in
urine of vaginal and cervical secretions obtained from
two healthy females (see Materials and Methods) were
analysed for CEA. The results are shown in table 4.
Other experiments showed that proteinuria does not
influence the CEA levels.
Tab. 4. Influence of vaginal and cervical secretion on urinary
CEA.
Extract
Extract a.
1:2
1:5
1:10
Extract b.
1:2
1:10
1:20
CEA (μ >/l)
>300
138
55
31
>300
>300
109
56
Discussion
Concerning the question of whether urinary CEA should
be expressed as the CEA/creatinine ratio or as CEA per
24-hour volume, we offer the following comment. CEA
in urine is produced by the urothelium and very
probably not excreted through the kidneys. This can
be concluded from the fact that patients with other
carcinomas and high blood CEA levels have normal
urinary CEA. For this reason a relation between urinary
CEA and creatiniiie excretion could not be expected to
exist. Furthermore, it is obvious that a CEA/creatinine
ratio cannot be calculated in cases in which the urinary
levels of CEA are below the borderline of detection.
Another argument is that the retention period of the
urine in the bladder does not seem to influence the con-
centration of urinary CEA. This may be concluded from
the data in table 5, showing nearly identical CEA levels
for a 3 hour and a 15 minute period. For clinical
evaluation, we have therefore used CEA levels measured
as μg/l in urines independently of the time of collection.
Like Hall et al. (2, 3) we found a wide range of urinary
CEA values in female controls. Our results differ from
theirs in that a larger percentage (43%, column II in
fig. 1) of values above 35 #g/l was found when measuring
midstream samples. This range may constitute a problem
in the interpretation of urinary CEA levels in female
patients with bladder carcinoma. The data from figure 1,
column VI, demonstrate that the use of catheter urine
solves this problem. Another conclusion which can be
drawn from figure 1 (column I and VI) is that the upper
limit of normal is 30 jigA- It should be noted that, if the
standard inhibition curve permitted measurement in the
20-30 Mg/1 range (7), values between 20-30 μg/l were
found in several cases in both groups. The borderline of
30 μg/l seems therefore real. Infection of the urinary tract
leads to a rise of urinary CEA in even a larger percentage
of cases than does bladder carcinoma (see fig. 1, columns
III and VII). In this respect it should be borne in mind
that urinary infections can be associated with very high
CEA levels. We therefore agree with Hall et al. (2) that
the possibility of urinary infection has to be excluded
before CEA levels are used for diagnostic purposes. We
disagree with these authors that the problem of false
positive values can be largely eliminated by the use of
midstream urine. The possibility of false negatives in
catheter urines must be accounted for (fig. 1, column IV).
Comparison with the data ofGuinan et al. (6) is difficult
Tab. 5. Relation of urinary CEA to the retention period of
urine in the bladder.
Patient
c5K
dK
dF
<SF
Period of retention
180 minutes
15 minutes
180 minutes
15 minutes
CEA(Mg/l)
48.5
50.0
24.0
24.5
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since these authors report mean CEA values in different
groups of urine samples but without distinguishing
between the presence and absence of infections or
between the presence and absence of tumours. Their
conclusion that urinary infection causes elevated CEA
levels which are not as high as in the case of a tumour,
is not sustained by our results. A possible explanation
might be the use of perchloric acid extraction by these
authors, which causes breakdown of CEA (7).
The above restrictions need some comment. Hall et al
(3) suggested on the basis of some experiments that the
occurrence of positive CEA values in female controls
might be caused by contamination of the urine with
vaginal and cervical secretions. Since no experimental
details were given and urines tested for CEA, if turbid,
are cleared by centrifugation, we considered it useful
to estimate the fraction of secretions soluble in urine
for CEA activity. The results outlined in table 4 con-
firm the suggestion of Hall et al. Additional support
lies in the positive and negative CEA value found in
midstream and catheter urine of the same female con-
trol (see Results). The concentration values given in
table 4 may not represent the real concentrations of
the substances in the secretion which exert CEA
activity. (The same may apply to CEA measured in
urines from bladders with a tumour or an infection).
Increased as well as normal CEA values were observed
with the common bacteria which can cause urinary
infection. Elevated CEA levels in infected urine there-
fore cannot be related to one type of bacterium. Our
results (see additional experiments) warrant the conclu-
sion that the bacteria themselves do not produce CEA.
The only explanation for the increase in urinary CEA
in infection seems to be that irritation or changing
of the bladder mucus by the bacteria leads to release
of CEA or substances with CEA-like activity. The fact
that CEA activity in infected urines, urines with vaginal
excretions and urines from bladders with a tumour show
parallelism to the standard curve, leads to the conclusion
that the active substances have antigenic groupings in
common. We tried to absoro-out the antiserum with
extracts of vaginal and cervical secretions in urine and
found no residual activity against colonic CEA. A more
precise description of the identity of the above sub-
stances cannot be given.
A relation between CEA levels and tumour diameters
might be expected. Statistically, urinary CEA levels are
indeed related to the tumour diameter (p = 0.035)
(tab. 1) but not to the stage of disease (p = 0.36) (tab. 2)
or to any of the histological parameters (p > 0.50 for
any of the parameters) (tab. 3). Increased urinary CEA
values are not only related to the bladder tumours,
since invasive growth of other tumours into the bladder
may also cause increased values.
Urinary CEA levels in patients with bladder carcinoma
were elevated in 53% of the cases without infection
(fig. 1, column IV). In none of 113 patients success-
fully treated for bladder carcinoma were increased
CEA values ever obtained. In other words: there were no
false positives results (fig. 1, column VI). Non in-
filtrating carcinomas of the bladder (so called papillo-
mata) of such patients did not cause increased values.
In view of these results, urinary CEA estimates are cli-
nically valuable for detection of tumour growth in the
bladder. To obtain diagnostically reliable CEA values
in females a catheter specimen is indispensable. Since
this is problematic in healthy females, urinary CEA
estimates for screening purposes will be confined in
practice to male subjects, (fig. 1, column I, IV and VI).
The follow-up findings will be presented in a subsequent
publication.
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